351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (182)
- Autoimmune Disorders (3)
- Blood Disorders (8)
- Cancer
(111)
- Bladder Cancer (1)
- (-) Brain Cancer (2)
- Breast Cancer (2)
- Gastrointestinal (3)
- (-) Gynecologic Cancer (3)
- Head and Neck Cancer (2)
- Kidney Cancer (3)
- Leukemia (9)
- Liver Cancer (1)
- Lung Cancer (14)
- Lymphoma (8)
- Multiple Myeloma (6)
- Pancreatic Cancer (1)
- Prostate Cancer (9)
- Sarcoma (4)
- Skin Cancer (5)
- Solid Tumors (7)
- Diabetes (1)
- Healthy Volunteers (3)
- Heart Disease (2)
- Infectious Disease (3)
- Neurological Disorders (16)
- Nutrition (1)
- Obstetrics & Gynecology (1)
- Pediatrics (15)
- Psychiatric Disorders (1)
- Transplant (16)
- Urology (1)
Displaying 1 - 5 of 5
Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Currently Recruiting
The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself or in combination with pembrolizumab, SOC chemotherapy, or TransCon TLR7/8 Agonist, or in combination with pembrolizumab and SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian cancer. The study drug, SL-…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with changes in the FGFR1, FGFR2 or FGFR3 genes. Pemigatinib (also referred as INCB054828) is an investigational drug that is being studied by Incyte Corporation (Sponsor) for use in the treatment of previously…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this study is to assess whether an investigational drug, called XmAb20717, has any effects on your cancer, and to determine if it is safe and well tolerated. XmAb20717 is a type of drug that can attach to 2 different proteins, call a bispecific antibody. These antibodies are designed to attach to a T-cell, a…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE